| Prev Close | 16.23 |
| Open | 16.23 |
| Day Low/High | 16.09 / 16.39 |
| 52 Wk Low/High | 11.02 / 17.99 |
| Volume | 213.80K |
| Avg Volume | 1.02M |
| Exchange | NASDAQ |
| Shares Outstanding | 101.14M |
| Market Cap | 1.62B |
| EPS | 1.20 |
| P/E Ratio | 13.59 |
| Div & Yield | N.A. (N.A) |
Follows Termination of CEO Mike Aguiar
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: EOCC, FET, IMMU, INVA, KMDA, SPH Downgrades: COR, EARN, EML, ENS, MSON, MYL, NCR, OFC, PBH, PCYO, THR, UBA, UBNT, UFS, WHG Initiations: None Read on to get TheStreet Quant Ratings' detailed report:
Innoviva, Inc. (NASDAQ: INVA) (the Company) today reported financial results for the fourth quarter and full year 2017.
Innoviva, Inc. (NASDAQ: INVA) announced today that it will report financial results for the fourth quarter and year ended December 31, 2017 after market close on February 8, 2017.
GlaxoSmithKline plc (LSE/NYSE:GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion...
Innoviva, Inc. (the "Company" or "Innoviva") (NASDAQ: INVA) today announced it implemented the Delaware Court of Chancery's order enforcing the oral settlement agreement with Sarissa Capital Domestic Fund LP and certain of...
GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced the filing of a supplemental New Drug Application (sNDA) with the US Food and Drug Administration (FDA) for the use of Trelegy Ellipta...
In recent trading, shares of Innoviva Inc have crossed above the average analyst 12-month target price of $13.00, changing hands for $13.06/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.
GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the European Commission has granted marketing authorisation for Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol,...
Innoviva, Inc. (NASDAQ: INVA) today announced that management will present at the following healthcare-focused investment banking conferences in November 2017: Credit Suisse 26th Annual Healthcare ConferenceNovember...
GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced positive data from a study comparing a once-daily long-acting muscarinic antagonist (LAMA) and a long-acting beta agonist (LABA)...
Innoviva, Inc. (NASDAQ: INVA) (the Company) today reported financial results for the third quarter of 2017.
Innoviva, Inc. (NASDAQ: INVA) announced today that it will report financial results for the third quarter ended September 30, 2017 after market close on Wednesday, October 25, 2017.
Innoviva, Inc. (NASDAQ: INVA) today announced that Michael W.
GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced positive headline results from the landmark phase III IMPACT study of Trelegy Ellipta, the first and only FDA approved once-daily single...
GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the US Food and Drug Administration (FDA) has approved once-daily, single inhaler triple therapy fluticasone...
GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion...
GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced positive results from the Salford Lung Study (SLS) in asthma have been simultaneously published in The Lancet journal and presented at...
Innoviva, Inc. (NASDAQ: INVA) today announced that Michael W.
In recent trading, shares of Innoviva Inc have crossed above the average analyst 12-month target price of $12.80, changing hands for $12.83/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.
Innoviva, Inc. ("Innoviva" or the "Company") (NASDAQ: INVA) today announced the closing of a $250 million Term B Loan (the "Term B Loan"), the proceeds of which were used to repay the remaining balance of the Company's LABA...
Innoviva, Inc. (NASDAQ: INVA) (the "Company" or "Innoviva") today announced that it closed its offering of the Company's 2.
Innoviva, Inc. (NASDAQ: INVA) (the "Company" or "Innoviva") today announced the pricing of $175 million aggregate principal amount of the Company's 2.
Innoviva, Inc. (NASDAQ: INVA) (the "Company" or "Innoviva") today announced its intention to offer, subject to market conditions and other factors, $175 million aggregate principal amount of convertible senior notes due...
Innoviva, Inc. (NASDAQ: INVA) (the Company) today reported financial results for the second quarter of 2017.
GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced a submission to the European Medicines Agency (EMA) for the extended use of once-daily Relvar Ellipta (fluticasone furoate/vilanterol,...
Innoviva, Inc. (NASDAQ: INVA) announced today that it will report financial results for the second quarter ended June 30, 2017 after market close on Wednesday, July 26, 2017.
Investors in Innoviva Inc saw new options begin trading this week, for the August 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the INVA options chain for the new August 18th contracts and identified one put and one call contract of particular interest.
